Effect of early treatment with fluvoxamine on risk of hospitalization among patients with COVID

View Content

This is the first large and randomized controlled trial test to test the efficacy of fluvoxamine for acute treatment of COVID-19. In the study, they found an absolute risk reduction of 5.0% and a 32% RR reduction.

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *